Immune response modifiers in the treatment of asthma: A PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology

Journal of Allergy and Clinical Immunology

Volumn 130, Issue 2, 2012, Pages 311-324

  Ballow, Mark ^a   Akdis, Cezmi A ^b   Casale, Thomas B ^c   Wardlaw, Andrew J ^d   Wenzel, Sally E ^e   Ballas, Zuhair ^f   Lötvall, Jan ^g  

^a CHILDREN S HOSPITAL OF BUFFALO   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GLENFIELD HOSPITAL   (United Kingdom)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^f UNIVERSITY OF IOWA   (United States)

^g UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

allergic diseases; asthma; Immune response modifiers; monoclonal antibodies

Indexed keywords

ACETYLSALICYLIC ACID; AMG 317; ANTIASTHMATIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BIMOSIAMOSE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR3 ANTAGONIST; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; GLITAZONE DERIVATIVE; IMATINIB; IMMUNOGLOBULIN E; IMMUNOMODULATING AGENT; INTERLEUKIN 13; INTERLEUKIN 4 RECEPTOR ALPHA ANTIBODY; INTERLEUKIN 5 ANTIBODY; INTERLEUKIN 9; LEBRIKIZUMAB; MEPOLIZUMAB; MONOCLONAL ANTIBODY; OMALIZUMAB; PIMECROLIMUS; PIOGLITAZONE; R 112; RESLIZUMAB; ROSIGLITAZONE; SALBUTAMOL; TACROLIMUS; UNCLASSIFIED DRUG;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ALLERGIC RHINITIS; ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATOPY; BRONCHODILATATION; CHRONIC MYELOID LEUKEMIA; CHRONIC URTICARIA; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; EOSINOPHIL; EOSINOPHILIC ESOPHAGITIS; FOOD ALLERGY; FORCED EXPIRATORY VOLUME; HEALTH CARE ORGANIZATION; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC MASTOCYTOSIS; T LYMPHOCYTE; TH2 CELL; UNSPECIFIED SIDE EFFECT;

EID: 84864484308     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2012.04.046     Document Type: Article

References (131)

1. T.A. Springer Cesar Milstein, the father of modern immunology Nat Immunol 3 2002 501 503
2. M. Berry, A. Morgan, D.E. Shaw, D. Parker, R. Green, and C. Brightling Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma Thorax 62 2007 1043 1049
3. A.J. Wardlaw, M. Silverman, R. Siva, I.D. Pavord, and R. Green Multi-dimensional phenotyping: towards a new taxonomy for airway disease Clin Exp Allergy 35 2005 1254 1262
4. S.E. Wenzel Asthma: defining of the persistent adult phenotypes Lancet 368 2006 804 813
5. P. Halder, I.D. Pavord, D.E. Shaw, M.A. Berry, M. Thomas, and C.E. Brightling Cluster analysis and clinical asthma phenotypes Am J Respir Crit Care Med 178 2008 218 224
6. J.L. Simpson, R. Scott, M.J. Boyle, and P.G. Gibson Inflammatory subtypes in asthma: assessment and identification using induced sputum Respirology 11 2006 54 61
7. G.P. Anderson Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogenous disease Lancet 372 2008 1107 1119
8. J. Lötvall, C.A. Akdis, L.B. Bacharier, L. Bjermer, T.B. Casale, and A. Custovic Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome J Allergy Clin Immunol 127 2011 355 360
9. H. Lin, K.M. Boesel, D.T. Griffith, C. Prussin, B. Foster, and F.A. Romero Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils J Allergy Clin Immunol 113 2004 297 302
10. C. Prussin, D.T. Griffith, K.M. Boesel, H. Lin, B. Foster, and T.B. Casale Omalizumab treatment downregulates dendritic cell FcepsilonRI expression J Allergy Clin Immunol 112 2003 1147 1154
11. R. Djukanovic, S.J. Wilson, M. Kraft, N.N. Jarjour, M. Steel, and K.F. Chung Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma Am J Respir Crit Care Med 170 2004 583 593
12. G.J. Rodrigo, H. Neffen, and J.A. Castro-Rodriguez Efficacy and safety of subcutaneous omalizumab versus placebo as add on therapy to corticosteroids for children and adults with asthma: a systematic review Chest 139 2011 28 35
13. R.G. Slavin, D. Ferioli, S. Tannenbaum, C. Martin, M. Blogg, and P.J. Lowe Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations J Allergy Clin Immunol 123 2009 107 113 e3
14. D. MacGlashan Jr. Therapeutic efficacy of omalizumab J Allergy Clin Immunol 123 2009 114 115
15. J. Bousquet, Z. Siergiejko, E. Swiebocka, M. Humbert, K. Rabe, and N. Smith Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma Allergy 66 2011 671 678
16. A. Nopp, S.G.O. Johansson, J. Adédoyin, J. Ankerst, M. Palmqvist, and H. Öman After 6 years with Xolair; a 3-year withdrawal follow-up Allergy 65 2010 56 60
17. L. Cox, T.A.E. Platts-Mills, I. Finegold, L. Schwartz, E.R. Simons, and D.V. Wallace American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis J Allergy Clin Immunol 120 2007 1373 1377
18. R. Tan, and J. Corren Omalizumab in the treatment of asthma Expert Rev Respir Med 5 2011 747 756
19. T. Casale, W. Busse, J. Kline, Z. Ballas, M. Moss, and R. Townley Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis J Allergy Clin Immunol 117 2006 134 140
20. K. Parks, and T. Casale Anti-immunoglobulin E monoclonal antibody administered with immunotherapy Allergy Asthma Proc 27 suppl 2006 S33 S36
21. J. Lane, J. Cheyney, T. Lane, D. Kent, and D. Cohen Treatment of recalcitrant atopic dermatitis with omalizumab J Am Acad Dermatol 54 2006 68 72
22. P. Warrier, and T. Casale Omalizumab in idiopathic anaphylaxis Ann Allergy Asthma Immunol 102 2009 257 258
23. P.G. Woodruff, B. Modrek, D.F. Choy, G. Jia, A.R. Abbas, and A. Ellwanger T-helper type 2-driven inflammation defines major subphenotypes of asthma Am J Respir Crit Care Med 180 2009 388 395
24. L.C. Borish, H.S. Nelson, M.J. Lanz, L. Claussen, J.B. Whitmore, and I.M. Agosti Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial Am J Respir Crit Care Med 160 1999 1816 1823
25. L.C. Borish, H.S. Nelson, J. Corren, G. Bensch, W.W. Busse, and J.B. Whitmore Efficacy of soluble IL-4 receptor for the treatment of adults with asthma J Allergy Clin Immunol 107 2001 963 970
26. S. Wenzel, D. Wilbraham, R. Fuller, E.B. Getz, and M. Longphre Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies Lancet 370 2007 1422 1431
27. J. Corren, W. Busse, E.O. Meltzer, L. Mansfield, G. Bensch, and J. Fahrenholz A randomized, controlled, phase 2 study of AMG317, an IL-4Rα antagonist, in patients with asthma Am J Respir Crit Care Med 181 2010 788 796
28. G.M. Gauvreau, L.P. Boulet, D.W. Cockcroft, J.M. Fitzgerald, C. Carlsten, and B.E. Davis Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma Am J Respir Crit Care Med 183 2011 1007 1014
29. J. Corren, R.F. Lemanske, N.A. Hanania, P.E. Korenblat, M.V. Merdad, and J.R. Arron Lebrikizumab treatment in adults with asthma N Engl J Med 365 2011 1088 1098
30. A.J. Wardlaw, and A.B. Kay The role of the eosinophil in the pathogenesis of asthma Allergy 42 1987 321 335
31. A.J. Wardlaw, S. Dunnette, G.J. Gleich, J.V. Collins, and A.B. Kay Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity Am Rev Respir Dis 137 1988 62 69
32. M.J. Leckie, A. ten Brinke, J. Khan, Z. Diamant, B.J. O'Connor, and C.M. Walls Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response Lancet 356 2000 2144 2148
33. P. Flood-Page, C. Swenson, I. Faiferman, J. Matthews, M. Williams, and L. Brannick A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma Am J Respir Crit Care Med 176 2007 1062 1071
34. J.C. Kips, B.J. O'Connor, S.J. Langley, A. Woodcock, H.A.M. Kerstjens, and D.S. Postma Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma Am J Respir Crit Care Med 167 2003 1655 1659
35. P. Haldar, I.D. Pavord, D.E. Shaw, M.A. Berry, M. Thomas, and C.E. Brightling Cluster analysis and clinical asthma phenotypes Am J Respir Crit Care Med 178 2008 218 224
36. I.D. Pavord, C.E. Brightling, G. Woltmann, and A.J. Wardlaw Non-eosinophilic corticosteroid unresponsive asthma [letter] Lancet 353 1999 2213 2214
37. P. Flood-Page, A. Menzies-Gow, A.B. Kay, and D.S. Robinson Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway Am J Respir Crit Care Med 167 2003 199 204
38. A.J. Wardlaw, C.E. Brightling, R. Green, G. Woltmann, P. Bradding, and I.D. Pavord New insights into the relationship between airway inflammation and asthma Clin Sci (Lond) 103 2002 201 211
39. I.D. Pavord, and A.J. Wardlaw The A to E of airway disease Clin Exp Allergy 40 2010 62 67
40. R.H. Green, C.E. Brightling, S. McKenna, B. Hargadon, D. Parker, and P. Bradding Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial Lancet 360 2002 1715 1721
41. P. Nair, M.M.M. Pizzichini, M. Kjarsgaard, M.D. Inman, A. Efthimiadis, and E. Pizzichini Mepolizumab for prednisone-dependent asthma with sputum eosinophilia N Eng J Med 360 2009 985 993
42. S.E. Wenzel Eosinophils in asthma - closing the loop or opening the door? N Engl J Med 360 2009 1026 1028
43. M.E. Rothenberg, A.D. Klion, F.E. Roufosse, J.E. Kahn, P.F. Weller, and H.U. Simon Treatment of patients with hypereosinophilic syndrome with mepolizumab N Engl J Med 358 2008 1215 1228
44. P. Halder, C.E. Brightling, B. Hargadon, S. Cupta, W. Monteiro, and A. Sousa Mepolizumab and exacerbations of refractory eosinophilic asthma N Engl J Med 360 2009 973 984
45. P. Flood-Page, A. Menzies-Gow, S. Phipps, S. Ying, A. Wangoo, and M.S. Ludwig Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics J Clin Invest 112 2003 1029 1036
46. M. Castro, S. Mathur, F. Hargreave, L.P. Boulet, F. Xie, and J. Young Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study Am J Respir Crit Care Med 184 2011 1125 1132
47. R. Kolbeck, A. Kozhich, M. Koike, L. Peng, C.K. Andersson, and M.M. Damschroder MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function J Allergy Clin Immunol 125 2010 1344 1353 e2
48. C.E. Brightling, R. Ward, G. Woltmann, P. Bradding, J.R. Sheller, and R. Dworski Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma Am J Respir Crit Care Med 162 2000 878 882
49. K. Mutalithas, C. Guillen, C. Day, C.E. Brightling, I.D. Pavord, and A.J. Wardlaw CRTH2 expression on T cells in asthma Clin Exp Immunol 161 2010 34 40
50. R. Pettipher, T.T. Hansel, and R. Armer Antagonism of the prostaglandin D2 receptors DPI and CRTH2 as an approach to treat allergic diseases Nat Rev Drug Discov 6 2007 313 325
51. T. Ulven, and E. Kostenis Novel CRTH2 antagonists: a review of patents from 2006 to 2009 Expert Opin Ther Pat 20 2010 1505 1530
52. E. Chevalier, J. Stock, T. Fisher, M. Dupont, M. Fric, and H. Fargeau Cutting edge: chemoattractant receptor-homologous molecule expressed on Th2 cells plays a restricting role on IL-5 production and eosinophil recruitment J Immunol 175 2005 2056 2060
53. T. Satoh, R. Moroi, K. Aritake, Y. Urade, Y. Kanai, and K. Sumi Prostaglandin D2 plays an essential role in chronic allergic inflammation of the skin via CRTH2 receptor J Immunol 177 2006 2621 2629
54. N.B. Barnes, I.D. Pavord, A. Chuchalin, J. Bell, M. Hunter, and T. Lewis A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC00459 in moderate persistent asthma Clin Exp Allergy 42 2012 38 48
55. M. Gallant, C. Beaulieu, C. Berthelette, J. Colucci, M. Crackower, and C. Dalton Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases Bioorg Med Chem Lett 21 2011 288 293
56. A.J. Wardlaw Molecular basis for selective eosinophil trafficking in asthma: a multistep paradigm J Allergy Clin Immunol 104 1999 917 926
57. K.L. Davenpeck, K.L. Berens, R.A. Dixon, B. Dupre, and B.S. Bochner Inhibition of adhesion of human neutrophils and eosinophils to P-selectin by the sialyl Lewis antagonist TBC1269: preferential activity against neutrophil adhesion in vitro J Allergy Clin Immunol 105 2000 769 775
58. D.G. Woodside, and P. Vanderslice Cell adhesion antagonists: therapeutic potential in asthma and chronic obstructive pulmonary disease BioDrugs 22 2008 85 100
59. K. Beeh, J. Beier, M. Meyer, R. Buhl, R. Zahlten, and G. Wolff Bimosiamose, an inhaled small molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over trial Pulm Pharmacol Ther 19 2006 233 241
60. J.E. Pease Targeting chemokine receptors in allergic disease Biochem J 434 2011 11 24
61. G.M. Gauvrear, L.P. Boulet, D.W. Cockcroft, A. Baatjes, J. Cote, and F. Deschesnes Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses Am J Respir Crit Care Med 177 2008 952 958
62. P. Vijayanand, K. Durkin, G. Hartmann, J. Morjaria, G. Seumois, and K.J. Staples Chemokine receptor 4 plays a key role in T cell recruitment into the airways of asthmatic patients J Immunol 184 2010 4568 4574
63. K. Mutalithas, C. Guillen, C. Raport, R. Kolbeck, D. Soler, and C.E. Brightling Expression of CCR8 is increased in asthma Clin Exp Allergy 40 2010 1175 1185
64. L. Tian, W. Li, J. Wang, Y. Zhang, Y. Zheng, and H. Qi The CKLF1-C19 peptide attenuates allergic lung inflammation by inhibiting CCR3 and CCR4-mediated chemotaxis in a mouse model of asthma Allergy 66 2011 287 297
65. R. Goswami, and M.H. Kaplan A brief history of IL-9 J Immunol 186 2011 3283 3288
66. H.C. Chang, S. Sehra, R. Goswami, W. Yao, Q. Yu, and G.L. Stritesky The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation Nat Immunol 11 2010 527 534
67. J. Kearley, J.S. Erjefalt, C.K. Andersson, E. Benjamin, C.P. Jones, and A. Robichaud IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways Am J Respir Crit Care Med 183 2011 865 875
68. V. Staudt, E. Bothur, M. Klein, K. Lingnau, S. Reuter, and N. Grebe Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells Immunity 33 2010 192 202
69. U.A. Temann, G.P. Geba, J.A. Rankin, and R.A. Flavell Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness J Exp Med 188 1998 1307 1320
70. U.A. Temann, Y. Laouar, E.E. Eynon, R. Homer, and R.A. Flavell IL9 leads to airway inflammation by inducing IL13 expression in airway epithelial cells Int Immunol 19 2007 1 10
71. A. Shimbara, P. Christodoulopoulos, A. Soussi-Gounni, R. Olivenstein, Y. Nakamura, and R.C. Levitt IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma J Allergy Clin Immunol 105 2000 108 115
72. J.M. Parker, C.K. Oh, C. LaForce, S.D. Miller, D.S. Pearlman, and C. Le Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma BMC Pulm Med 11 2011 11 21
73. D.E. Smith IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma Clin Exp Allergy 40 2010 200 208
74. A. Shikotra, D.F. Choy, C.M. Ohri, E. Doran, C. Butler, and B. Hargadon Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma J Allergy Clin Immunol 129 2012 104 111 e1-9
75. C.J. Oliphant, J.L. Barlow, and A.N. McKenzie Insights into the initiation of type 2 immune responses Immunology 134 2011 378 385
76. C.J. Corrigan, W. Wang, Q. Meng, C. Fang, G. Eid, and M.R. Caballero Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses J Allergy Clin Immunol 128 2011 116 124
77. W.W. Busse, J.W. Baker, B.L. Charous, P. Chervinsky, K.T. Kim, and G.N. Gross Preliminary safety and efficacy of daclizumab in the treatment of patients with moderate to severe chronic persistent asthma J Allergy Clin Immunol 113 suppl 2004 S286
78. H.S. Nelson, W.W. Busse, E. Israel, J.W. Baker, B.L. Charous, and K.T. Kim Daclizumab improves asthma control in patients with refractory asthma J Allergy Clin Immunol 115 suppl 2005 S134
79. T.R. Sornasse, W. Hong, R. Schreck, Y. Zhang, J. Sheridan, and J. Shi Daclizumab in vitro inhibits the secretion of pro-asthmatic and pro-inflammatory cytokines by activated T-cells J Allergy Clin Immunol 115 suppl 2005 S73
80. W.W. Busse, E. Israel, H.S. Nelson, J.W. Baker, B.L. Charous, and D.Y. Young Daclizumab improves asthma control in patients with moderate to severe persistent asthma Am J Respir Crit Care Med 178 2008 1002 1008
81. H. Reiser, and M.J. Stadecker Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases N Engl J med 335 1996 1369 1377
82. T. Kawano, H. Matsuse, Y. Kondo, I. Machida, S. Saeki, and S. Tomari Tacrolimus reduces urinary excretion of leukotriene E(4) and inhibits aspirin-induced asthma to threshold dose of aspirin J Allergy Clin Immunol 114 2004 1278 1281
83. D.D. Stevenson, P.K. Mehra, A.A. White, S. Gupta, K.M. Woessner, and R.A. Simon Failure of tacrolimus to prevent aspirin-induced respiratory reactions in patients with aspirin-exacerbated respiratory disease J Allergy Clin Immunol 116 2005 755 760
84. H. Virtanen, A. Remitz, P. Malmberg, P. Rytilä, T. Metso, and T. Haahtela Topical tacrolimus in the treatment of atopic dermatitis - does it benefit the airways? A 4-year open follow-up J Allergy Clin Immunol 120 2007 1464 1466
85. C.D. Mol, D.R. Dougan, T.R. Schneider, R.J. Skene, M.L. Kraus, and D.N. Scheibe Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase J Biol Chem 279 2004 31655 31663
86. P.U. Ogbogu, B.S. Bochner, J.H. Butterfield, G.J. Gleich, J. Huss-Marp, and J.E. Kahn Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy J Allergy Clin Immunol 124 2009 1319 1325e
87. E.O. Meltzer, D.L. Hamilos, J.A. Hadley, D.C. Lanza, B.F. Marple, and R.A. Nicklas Rhinosinusitis: Developing guidance for clinical trials J Allergy Clin Immunol 118 suppl 2006 S17 S61
88. M.G. Belvisi, and D.J. Hele Peroxisome proliferator-activated receptors as novel targets in lung disease Chest 134 2008 152 157
89. G.M. Denning, and L.L. Stoll Peroxisome proliferator-activated receptors: potential therapeutic targets in lung disease? Pediatr Pulmonol 41 2006 23 34
90. G. Woerly, K. Honda, M. Loyens, J.P. Papin, M. Auwerx, and B. Staels Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation J Exp Med 198 2003 411 421
91. M. Spears, I. Donnelly, L. Jolly, M. Brannigan, K. Ito, and C. McSharry Bronchodilatory effect of the PPAR-gamma agonist rosiglitazone in smokers with asthma Clin Pharmacol Ther 86 2009 49 53
92. M.S. Sandhu, V. Dimov, T. Romero, T. Wichman, and T.B. Casale Effects of rosiglitazone on airway hyperresponsiveness and obstruction in asthma J Allergy Clin Immunol 5 2010 AB66
93. M. Zhu, L. Flynt, S. Ghosh, M. Mellema, A. Banerjee, and E. Williams Anti-inflammatory effects of thiazolidinediones in human airway smooth muscle cells Am J Respir Cell Mol Biol 45 2011 111 119
94. A.M. Krieg Therapeutic potential of toll-like receptor 9 activation Nat Rev Drug Discov 5 2006 471 484
95. P.S. Creticos, J.T. Schroeder, R.G. Hamilton, S.L. Balcer-Whaley, A.P. Khattignavong, and R. Lindblad Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis N Engl J Med 355 2006 1445 1455
96. D. Bernstein, N. Segall, A. Nayak, T. Casale, P. Korenblat, and E. Martins Safety and efficacy of the novel vaccine Tolamba in ragweed allergic adults, a dose finding study J Allergy Clin Immunol 119 suppl 2007 S78 S79
97. G.M. Gauvreau, E.M. Hessel, L. Boulet, R.L. Coffman, and P.M. O'Byrne Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses Am J Respir Crit Care Med 174 2006 15 20
98. G. Senti, P. Johansen, S. Haug, C. Bull, C. Gottschaller, and P. Muller Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial Clin Exp Allergy 39 2009 562 570
99. L. Klimek, J. Willers, A. Hammann-Haenni, O. Pfaar, H. Stocker, and P. Mueller Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study Clin Exp Allergy 41 2011 1305 1312
100. A. Blaziene, P. Leisyte, B. Sitkauskine, L. Kits, M. Savisaar, and V. Lozovskis CYT003-QbG10, a novel allergen-independent immunotherapy, shown to be safe and efficacious in placebo-controlled phase II study Ann Allergy Asthma Immunol 102 2009 A8
101. W. Renner, K. Beeh, C. Schilder, F. Wagner, F. Kanniess, and I. Naudts Novel TLR-9 agonist CYT003-QbG10 shown to improve asthma control in placebo-controlled phase II clinical trial Am J Respir Crit Care Med 183 2011 A4063
102. A. Musarra, D. Bignardi, C. Troise, and G. Passalacqua Long-lasting effect of a monophosphoryl lipid-adjuvanted immunotherapy to Parietaria. A controlled field study Eur Ann Allergy Clin Immunol 42 2010 115 119
103. M. Rosewich Ultra-short course immunotherapy in children and adolescents during a 3-yrs post-marketing surveillance study Pediatr Allergy Immunol 21 2009 e185 e189
104. M. Rosewich, J. Schulze, O. Eickmeier, T. Telles, M.A. Rose, and R. Schubert Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children Clin Exp Immunol 160 2010 403 410
105. O. Pfaar, C. Barth, C. Jaschke, K. Hormann, and L. Klimek Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study Int Arch Allergy Immunol 154 2010 336 344
106. M.J. Duechs, C. Hahn, E. Benediktus, M. Werner-Klein, A. Braun, and H.G. Hoymann TLR agonist mediated suppression of allergic responses is associated with increased innate inflammation in the airways Pulm Pharmacol Ther 24 2011 203 214
107. L.P. Van, E. Bardel, S. Gregoire, J. Vanoirbeek, E. Schneider, and M. Dy Treatment with the TLR7 agonist R848 induces regulatory T-cell-mediated suppression of established asthma symptoms Eur J Immunol 41 2011 1992 1999
108. C. Xirakia, O. Koltsida, A. Stavropoulos, A. Thanassopoulou, V. Aidinis, and P. Sideras Toll-like receptor 7-triggered immune response in the lung mediates acute and long-lasting suppression of experimental asthma Am J Respir Crit Care Med 181 2010 1207 1216
109. F. Horak, P. Zieglmayer, R. Zieglmayer, P. Lemell, M. Newkirk, and K. Manjarrez Intranasal TLR 8 agonist (VTX-1463) significantly improves symptoms of allergic rhinitis in a randomized, placebo-controlled trial J Allergy Clin Immunol 127 2011 AB199
110. S.J. Lee, and A. Kavanaugh Adverse reactions to biologic agents: focus on autoimmune disease therapies J Allergy Clin Immunol 116 2005 900 905
111. J. Bieber, and A. Kavanaugh Consideration of the risk and treatment of TB in patients with rheumatoid arthritis receiving biologic treatments Rheum Dis Clin North Am 30 2004 257 270
112. R.F. van Vollenhoven Benefits and risks of biological agents: lymphomas Clin Exp Allergy 22 suppl 2004 S122 S125
113. R. Koivuniemi, L. Paimela, R. Suomalainen, and M. Leirisalo-Repo Malignancies in patients with rheumatoid arthritis Scand J Rheumatol 40 2011 154 155
114. M. Magnano, W.H. Robinson, and M.C. Genovese Demyelination and the use of TNF inhibition Clin Exp Allergy 22 suppl 2004 S134 S140
115. D. Abramowicz, A. Crusiaux, and M. Goldman Anaphylactic shock after retreatment with OKT3 monoclonal antibody N Engl J Med 327 1992 736
116. M.J. Wasserman, D.A. Weber, J.A. Guthrie, V.P. Bykerk, P. Lee, and E.C. Keystone Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, anti-histamine pre-treatment, and infusion number J Rheumatol 31 2004 1912 1917
117. F. Baert, M. Norman, S. Vermeire, G. Van Assche, G. D'Haens, and A. Carbonez Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease N Engl J Med 348 2003 601 608
118. P. Campi, M. Benucci, M. Manfredi, and P. Demoly Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-α antagonists Curr Opin Allergy Clin Immunol 7 2007 393 403
119. A. Youdim, E.A. Vasiliauskas, S.R. Targan, K.A. Papadakis, A. Ippoliti, and M.C. Dubinsky A pilot study of adalimumab in infliximab-allergic patients Inflamm Bowel Dis 10 2004 333 338
120. P. Brennan, T.R. Bouza, F.I. Hsu, and D.E. Sloane Hypersensitivity reactions to monoclonal antibodies: 105 desensitizations in 23 patients, from evaluation to treatment J Allergy Clin Immunol 124 2009 1259 1266
121. K.S. Price, and R.G. Hamilton Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy Allergy Asthma Proc 28 2007 313 319
122. W. Berger, N. Gupta, M. McAlary, and A. Fowler-Taylor Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma Ann Allergy Asthma Immunol 91 2003 182 188
123. H.A. Sampson, A. Munoz-Furlong, R.L. Campbell, N.F. Adkinson Jr., S.A. Bock, and A. Branum Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium J Allergy Clin Immunol 117 2006 391 397
124. A.A. Cruz, F. Lima, E. Sarinho, G. Ayre, C. Martin, and H. Fox Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection Clin Exp Allergy 37 2007 197 207
125. C.H. Chung, B. Mirakhur, E. Chan, Q.T. Le, J. Berlin, and M. Morse Cetuximab-induced anaphylaxis and IgE specific for galactose α-1,3-galactose N Eng J Med 358 2008 1109 1117
126. S.P. Commins, and T.A.E. Platts-Mills Allergenicity of carbohydrates and their role in anaphylactic events Curr Allergy Asthma Rep 10 2010 29 33
127. G. Suntharalingam, M.R. Perry, S. Ward, S.J. Brett, A. Castello-Cortes, and M.D. Brunner Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 N Engl J Med 355 2006 1018 1028
128. A. Beck, T. Wurch, C. Bailly, and N. Corvaia Strategies and challenges for the next generation of therapeutic antibodies Nat Rev Immunol 10 2010 345 352
129. R. Linke, A. Klein, and D. Steimetz Catumaxomab: clinical development and future directions MAbs 2 2010 129 136
130. C. Wu, H. Ying, S. Bose, R. Miller, L. Medina, and L. Santora Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-Ig) molecules MAbs 1 2009 339 347
131. S.E. Wenzel, P.J. Barnes, E.R. Bleecker, J. Bousquet, W. Busse, and S.E. Dahlén A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma Am J Respir Crit Care Med 179 2009 549 558